Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30963922 | 1.00 | CA1 (0.42) | CA1CA2CA12CA7CA9 | |
| SCHEMBL14898151 | 0.89 | ERN1 (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL960031 | 0.88 | ALDH1A1 (0.43) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3454613 | 0.85 | KDM4E (0.46) | CA1CA2CA12CA7CA9 | |
| SCHEMBL18145744 | 0.85 | CA1 (0.54) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4161409 | 0.85 | GABRA1 (0.38) | CA1CA2CA12CA9CA14 | |
| SCHEMBL17181493 | 0.84 | KDM4E (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL426746 | 0.84 | MAPT (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30803515 | 0.84 | KDM4E (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30963854 | 0.84 | CA12 (0.41) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260022124-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV MINNESOTA (US) | 2026-01-22 | — | — | US | disclosed |
| US-12522587-B2 | Cancer treatments targeting cancer stem cells | REMEDY PLAN, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4169575-B1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMA (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4279476-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-22 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4276092-A1 | COMPOUND LIBRARY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-15 | — | — | EP | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007081569-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-7022699-B2 | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| EP-1377584-B1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES AS VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | WYETH CORP (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1377584-A1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES AS VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | WYETH | 2002-12-26 | — | — | US | disclosed |
| WO-2002083681-A1 | NOVEL CYCLOHEXENYL PHENYL DIAZEPINES VASOPRESSIN AND OXYTOCIN RECEPTOR MODULATORS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022124-A1 | THERAPEUTIC COMPOUNDS AND METHODS | NR5A1, CYP17A1, CNR1 | CA1 205/4885CA2 158/4885CA12 331/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | CA1 31/4885CA2 791/4885CA12 74/4885 |
| US-20020198196-A1 | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | OXTR, AVPR2, AVPR1B | CA1 2054/4885CA2 3247/4885CA12 3782/4885 |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | CA1 3544/4885CA2 1273/4885CA12 4559/4885 |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | CA1 76/4885CA2 163/4885CA12 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.